Thermo Fisher Scientific to acquire QIAGEN

March 4, 2020

Thermo Fisher Scientific, the world leader in serving science, and QIAGEN, a Germany-based pharmaceutical company, have agreed to combine their businesses and create a leading global biotechnology company.  

This was the first German/US public offer ever made for a Dutch NV company. As lead counsel to QIAGEN, we led an international team of lawyers advising QIAGEN on this multi-billion cross-border transaction.


Read more about this deal here.


De Brauw team: Arne Grimme, Martin van Olffen, Bernard Spoor, Casper Nagtegaal, Frank Hamming, Eveline de Waard, Ioana Patrascu, Matthijs Verwer, Maarten van der Weijden, Klaas Versteeg and Pim Siemons.


We keep track of you on our site with cookies, in order to offer the basic functionality of the website and generate user statistics on an anonymous basis to make our website more user-friendly. We do not use or share your data with third parties for advertising purposes.